Cognition Therapeutics
Market cap $59.9M 95.1M shares (10-Q, Nov 2, 2026) × $0.630 close Nov 17, 2026
Most recent annual filing: 2026-01-15
- Capital raise / ATM financing2H 2026Capital raise / ATM financing, 2H 2026, notable
- START Phase 2 MCI Ph22027START Phase 2 MCI Ph2, 2027, material
- Nasdaq listing compliance updateMay 3, 2027Nasdaq listing compliance update, May 3, 2027, routine
- START DLB Ph3 topline2H 2027START DLB Ph3 topline, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Discontinued (1)
- zervimesine — Geographic Atrophy · voluntarily discontinued to focus resources on dementia programs in AD and DLB; not related to safety concerns
Capital (as filed)
- Cash
- $30.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$3.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $31.5M cash, runway into the fourth quarter of 2027 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (14)
- 2026-11-06 UPDATE: Cognition Therapeutics (CGTX) - The Nasdaq Clock Starts Ticking 🔒 Paid
- 2026-10-22 UPDATE: Cognition Therapeutics (CGTX) - The Endpoint Is Locked. Now Comes the Bill. ★ Distilled Pro
- 2026-09-30 UPDATE: Cognition Therapeutics (CGTX) - The Endpoint Meeting Has a Date (and a Different Division) 🔒 Paid
- 2026-08-07 UPDATE: Cognition Therapeutics (CGTX) — The Dilution Gap Keeps Shrinking, and the Patent Clock Just Moved Ten Years 🔒 Paid
- 2026-06-24 UPDATE: Cognition Therapeutics (CGTX) — The Minutes Landed. The Stock Didn’t Get the Memo. 🔒 Paid
- 2026-05-21 UPDATE: Cognition Therapeutics (CGTX) - The May 20 Meeting Cleared, Now We Wait for the Minutes 🔒 Paid
- 2026-05-08 UPDATE: Cognition Therapeutics (CGTX) - The Psychosis Catalyst Has a Date 🔒 Paid
- 2026-03-29 UPDATE: Cognition Therapeutics (CGTX) - The Reality Check and a 30% Haircut 🔒 Paid
- 2026-03-22 UPDATE: Cognition Therapeutics (CGTX) – Showing the Math at AD/PD 🔒 Paid
- 2026-03-07 UPDATE: Cognition Therapeutics (CGTX) – The Psychosis Pivot is a Regulatory Masterstroke 🔒 Paid
- 2026-02-07 UPDATE: Cognition Therapeutics (CGTX) – Patients Vote Yes (But the Market Still Seems to Be Waiting) 🔒 Paid
- 2026-01-30 UPDATE: Cognition Therapeutics (CGTX) - The Phase 3 Dream Just Became a Phase 2b Reality Check 🔒 Paid
- 2026-01-07 UPDATE: Cognition Therapeutics (CGTX) Prints Some Receipts for DLB 🔒 Paid
- 2026-01-01 Cognition Therapeutics (CGTX): Scientific Due Diligence for Zervimesine 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (14 calls)
Every verdict Biotech Distilled has published on Cognition Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-01 Watch Cognition Therapeutics (CGTX): Scientific Due Diligence for Zervimesine The Dilution Gap is too risky for an immediate entry; wait for the inevitable capital raise before buying the dip into the DLB and Dry AMD assets.
- 2026-01-07 Watch UPDATE: Cognition Therapeutics (CGTX) Prints Some Receipts for DLB Peer-reviewed SHIMMER publication increases scientific conviction but the Dilution Gap is unchanged; wait for FDA meeting minutes and the financing event before entering.
- 2026-01-30 Watch UPDATE: Cognition Therapeutics (CGTX) - The Phase 3 Dream Just Became a Phase 2b Reality Check FDA redirected the DLB program to a Phase 2b instead of a Phase 3, extending the timeline and widening the dilution gap, making the entry even less attractive near-term.
- 2026-02-07 Watch UPDATE: Cognition Therapeutics (CGTX) – Patients Vote Yes (But the Market Still Seems to Be Waiting) EAP extension is a soft efficacy signal but not a catalyst; stay on the sidelines until FDA minutes drop and the financing path is clear.
- 2026-03-07 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) – The Psychosis Pivot is a Regulatory Masterstroke The pivot to a registrational path for DLB Psychosis is a brilliant strategic move that makes a successful capital raise much more likely; buy after the financing event clears the dilution overhang.
- 2026-03-22 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) – Showing the Math at AD/PD Conference presentation validates the DLB psychosis narrative and courts institutional investors, but the dilution gap remains; wait for the financing before entering.
- 2026-03-29 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) - The Reality Check and a 30% Haircut Annual filings confirm the $75M ATM is loaded and imminent dilution is being priced in; avoid catching the falling knife and wait for the financing to clear before buying.
- 2026-05-08 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) - The Psychosis Catalyst Has a Date The May 20 FDA Division of Psychiatry meeting is a binary de-risking event; existing holders should hold into it, while new entrants are paying retail for anticipated good news.
- 2026-05-21 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) - The May 20 Meeting Cleared, Now We Wait for the Minutes The May 20 meeting kept the registrational path alive but the June minutes are the actual de-risking document; holders may trim a portion while keeping a stub for the minutes.
- 2026-06-24 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) — The Minutes Landed. The Stock Didn't Get the Memo. FDA minutes confirmed DLB psychosis is an approvable outcome with a 9-month NPI-based Phase 3 design; the stock's decline is driven by financing-overhang anticipation, not the regulatory outcome, making the asymmetry more favorable for buyers.
- 2026-08-07 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) — The Dilution Gap Keeps Shrinking, and the Patent Clock Just Moved Ten Years Cash rose sequentially, runway extended to Q4 2027, R&D cut 56% YoY, and a new composition-of-matter patent extends protection to 2045, materially improving the risk profile while the endpoint statistics remain the one open regulatory item.
- 2026-09-30 Hold UPDATE: Cognition Therapeutics (CGTX) - The Endpoint Meeting Has a Date (and a Different Division) The October 20 FDA Type C meeting with the Division of Neurology (not Psychiatry) adds uncertainty to the endpoint statistics; holders should wait for the formal minutes rather than adding, and sidelined readers should wait for the outcome before entering.
- 2026-10-22 Speculative buy speculative UPDATE: Cognition Therapeutics (CGTX) - The Endpoint Is Locked. Now Comes the Bill. FDA aligned on NPI-2 primary endpoint and 9-month Phase 3 design, retiring the last open regulatory question; the remaining risk is financing at a sub-$1 share price, so wait for the bankers to fill the tank before entering.
- 2026-11-06 Watch UPDATE: Cognition Therapeutics (CGTX) - The Nasdaq Clock Starts Ticking A Nasdaq deficiency letter, likely reverse split ahead, and an unfunded Phase 3 make the expected path reverse-split-then-raise, which usually pushes the price down first; move to Watch List until a funded Phase 3 on a post-split share count is in place.
- Long call · opened Mar 9, 2026 at $1.08 · closed Nov 6, 2026 (downgraded to WATCH from long) at $0.687 · -36.4% vs XBI +19.7%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (32)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseCognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
- Nov 9, 2026ReleaseCognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
- Nov 5, 2026ReleaseCognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations, listing notice · EX-99.1 EXHIBIT 99.1→ BD updateNasdaq sent the deficiency letter — CGTX officially has until May 3, 2027 to get back above $1.00. The Q3 print shows the balance sheet is holding up better than feared, but the listing clock is now ticking in writing.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseCognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
- Oct 22, 2026ReleaseCognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies→ BD updateSummary on the 8-K
- Oct 22, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1→ BD updateThe FDA alignment on Phase 3 design is the milestone I've been pointing at since September — NPI-2 (hallucinations + delusions) is the locked primary endpoint, ADCS-ADL the key secondary, 100 mg / 9-month / randomized design confirmed. The stock's -6.2% session move despite the news demands explanation.
- Oct 13, 2026ReleaseCognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
- Sep 29, 2026ReleaseCognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB→ BD updateThe single open regulatory item that's been blocking the Phase 3 start just got a date: October 20, Cognition meets with the FDA Division of Neurology to nail down the NPI endpoint statistics for the DLB psychosis registrational trial — the last formal gate before the trial clock starts.
- Sep 8, 2026ReleaseCognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
- Aug 7, 202610-QQuarterly report
- Aug 6, 2026ReleaseCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Jul 13, 2026ReleaseCognition Therapeutics Participating in Fireside Chat at B. Riley Securities’ Mind, Muscle & Vision Summit
- Jun 24, 2026ReleaseCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting MinutesBD extracted 1 program update from this document → CGTX pipeline
- Jun 24, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Jun 18, 20268-KCurrent report: shareholder vote
- Jun 16, 2026ReleaseCognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
- Jun 4, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Jun 1, 2026ReleaseCognition Therapeutics Participating in Upcoming Investor Conferences
- May 21, 2026ReleaseCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- May 21, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- May 14, 2026ReleaseCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
- May 8, 202610-QQuarterly report
- May 7, 2026ReleaseCognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
- May 7, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 27, 2026DEF 14AProxy statement
- Mar 26, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 26, 202610-KAnnual report
- Mar 2, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Apr 27, 2026ARSAnnual report to shareholders
- Mar 26, 2026S-8Employee plan registration